These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Trying times at the FDA--the challenge of ensuring the safety of imported pharmaceuticals. Schweitzer SO N Engl J Med; 2008 Apr; 358(17):1773-7. PubMed ID: 18434648 [No Abstract] [Full Text] [Related]
26. Is it a cosmetic, a drug, or both? (Or is it soap?). Center for Safety and Applied Nutrition/Office of Cosmetics and Colors US Food and Drug Administration Plast Surg Nurs; 2008; 28(4):195-7. PubMed ID: 19092587 [No Abstract] [Full Text] [Related]
27. Injecting Safety into Supplements - Modernizing the Dietary Supplement Law. Cohen PA; Bass S N Engl J Med; 2019 Dec; 381(25):2387-2389. PubMed ID: 31851798 [No Abstract] [Full Text] [Related]
28. The FDA and deference lost: a self-inflicted wound or the product of a wounded agency? A response to Professor O'Reilly. Vladeck DC Cornell Law Rev; 2008 Jul; 93(5):981-1002. PubMed ID: 18618967 [No Abstract] [Full Text] [Related]
29. Court rules generic drug companies not responsible for adverse outcomes. Kouros N Monash Bioeth Rev; 2013 Sep; 31(2):23-4. PubMed ID: 24844072 [No Abstract] [Full Text] [Related]
30. A defense of the learned intermediary doctrine. Goetz RB; Growdon KR Food Drug Law J; 2008; 63(2):421-38. PubMed ID: 18561470 [No Abstract] [Full Text] [Related]
31. Prescription for fairness: a new approach to tort liability of brand-name and generic drug manufacturers. Rostron A Duke Law J; 2011 Feb; 60(5):1123-91. PubMed ID: 21365961 [TBL] [Abstract][Full Text] [Related]
32. The FDA: is it protecting the public with one hand tied behind its back? Shedlin RS Law Med Health Care; 1992; 20(3):253-7. PubMed ID: 1434771 [No Abstract] [Full Text] [Related]
33. Pharma industry's bitter pill ... could be impetus for devicemaker legislation, too. Blesch G Mod Healthc; 2009 Mar; 39(10):11. PubMed ID: 19610180 [No Abstract] [Full Text] [Related]
34. Pharmaceutical industry wins "round one" in protections against product liability claims. Gatty B Hosp Formul; 1995 Apr; 30(4):238, 237. PubMed ID: 10141868 [No Abstract] [Full Text] [Related]
35. Pros and cons of off-label promotion investigations and prosecutions. Loucks MK Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041 [No Abstract] [Full Text] [Related]
36. The case for preemption of prescription drug failure-to-warn claims. Kim CH Food Drug Law J; 2007; 62(2):399-422. PubMed ID: 17632969 [No Abstract] [Full Text] [Related]
37. Drug counterfeiting burden remains a guess, experts say. Traynor K Am J Health Syst Pharm; 2009 Jul; 66(14):1246-8. PubMed ID: 19574593 [No Abstract] [Full Text] [Related]
38. Off-label drug use and promotion: balancing public health goals and commercial speech. Kesselheim AS Am J Law Med; 2011; 37(2-3):225-57. PubMed ID: 21847880 [No Abstract] [Full Text] [Related]
39. The dangers of intravenous promethazine administration. Paparella S J Emerg Nurs; 2007 Feb; 33(1):53-6; quiz 92. PubMed ID: 17258055 [No Abstract] [Full Text] [Related]
40. Tort claims and federal regulation of medical devices vs pharmaceuticals. Green M JAMA; 2009 Sep; 302(11):1169; author reply 1169-70. PubMed ID: 19755694 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]